Skin and Joints Podcast

It Takes Two to TYK-2 PART 2: Zooming in on Deucravacitinib and What It Means for Your Patients with PsO

Episode Summary

🎧 🎉TYK-TOK we’re ready to rock PART 2! 🎙️🎙️ The Skin and Joints Podcast Team continues the conversation with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis. 🛎️ Deucravacitinib is finally here! And we're going to be looking at fresh new data that could change your clinical practice. We also break it down with our expert Faculty so you don't need to :)  🧵Where do our experts see the overall place deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world? 🧵How does it compare with other biologics and non-biologic treatments? 🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? Episode Learning Objectives Describe the overall place of deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world Examine the clinical efficacy associated with deucravacitinib and other select biologic and nonbiologic treatments in patients with moderate to severe PsO Explore the correlations between responses on clinical and patient reported outcome (PRO) measures from  pooled data from POETYK PSO-1 and PSO-2 pivotal trials Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis subgroup analyses pooled PSO-1 and PSO-2 data ta

Episode Notes

🎧 🎉TYK-TOK we’re ready to rock PART 2!

🎙️🎙️ The Skin and Joints Podcast Team continues the conversation with dermatologist dynamic duo Dr.Chih-Ho Hong and Dr.Irina Turchin who respectively lend their real world perspectives on a brand new oral therapy for our patients with moderate to severe psoriasis.

 🛎️ Deucravacitinib is finally here! And we're going to be looking at fresh new data that could change your clinical practice.  We also break it down with our expert Faculty so you don't need to :) 

🧵Where do our experts see the overall place  deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world?

🧵How does it compare with other biologics and non-biologic treatments?

🫳 How effective is it for patients specifically with moderate to severe scalp, nail and palmoplantar psoriasis? 

Episode Learning Objectives

• Describe the overall place of deucravacitinib in the therapeutic treatment pathway for moderate to severe psoriasis in the real world
• Examine the clinical efficacy associated with deucravacitinib and other select  biologic and nonbiologic treatments in patients with moderate to severe PsO
• Explore the correlations between responses on clinical and patient reported outcome (PRO) measures from  pooled data from POETYK PSO-1 and PSO-2 pivotal trials
• Evaluate the efficacy of deucravacitinib treatment in patients with moderate to severe scalp, nail, and palmoplantar psoriasis  subgroup analyses pooled PSO-1 and PSO-2 data